Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions

7/15/24 7:38:49 AM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $MDWD alert in real time by email

Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (NASDAQ:MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). MediWound, a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement, has a vision to improve the existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.

Debridement is a standard of care step to prepare the wound bed for healing and can help in the management of infection. It involves the removal of dead or devitalised tissue from a wound.

Get the next $MDWD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MDWD

Date	Price Target	Rating	Analyst
7/16/2024	$25.00 → $30.00	Buy	Maxim Group
12/22/2022	$11.00	Buy	Maxim Group
7/18/2022	$7.00	Outperform	Oppenheimer
8/17/2021	$10.00 → $9.00	Buy	Aegis Capital
8/11/2021	$7.00 → $6.50	Buy	HC Wainwright & Co.

More analyst ratings

MediWound to Report Third Quarter 2024 Financial Results
YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-833-630-1956Israel:1-80-921-2373International:1-412-317-1837Webcast:Click HERE To access the call, participants should dial the app
11/12/24 8:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable Market; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference Call Today, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update. "This has been another
8/14/24 7:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care
MediWound to Report Second Quarter 2024 Financial Results
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-833-630-1956Israel:1-80-921-2373International:1-412-317-1837Webcast:Click HERE To access the call, participants should dial
8/2/24 8:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o
11/21/23 7:00:00 AM ET
$ENLV
$MDWD
Biotechnology: Pharmaceutical Preparations
Health Care
Medicinal Chemicals and Botanical Products
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit
11/8/23 7:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi
3/16/23 7:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care

MediWound to Report Third Quarter 2024 Financial Results
YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-833-630-1956Israel:1-80-921-2373International:1-412-317-1837Webcast:Click HERE To access the call, participants should dial the app
11/12/24 8:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx® BLA submission and strengthen commercialization strategy YAVNE, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will be initiating a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment (marketed as SANTYL® in the U.S. and IRUXOL® in Europe) for the treatment of venous leg ulcers (VLUs). Scheduled to commence in 2025, this Phase II study will run concurrently with the Company'
10/10/24 7:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET. To attend the virtual fireside chat, please register here. In addition, the MediWound management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to sched
10/8/24 8:00:00 AM ET
$MDWD
Medicinal Chemicals and Botanical Products
Health Care

Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions

Chat with this insight

Recent Analyst Ratings for $MDWD

$MDWD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

$MDWD SEC Filings

SEC Form 6-K filed by MediWound Ltd.

SEC Form EFFECT filed by MediWound Ltd.

SEC Form 424B3 filed by MediWound Ltd.

$MDWD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

SEC Form SC 13G filed by MediWound Ltd.

$MDWD Financials

Live finance-specific insights

$MDWD Leadership Updates

Live Leadership Updates

$MDWD Press Releases

Fastest customizable press release news feed in the world

$MDWD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$MDWD Market Insights

Live Market Insights

MediWound to Report Third Quarter 2024 Financial Results

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound to Report Second Quarter 2024 Financial Results

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

MediWound to Report Third Quarter 2024 Financial Results

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

Maxim Group reiterated coverage on MediWound with a new price target

Maxim Group initiated coverage on MediWound with a new price target

Oppenheimer resumed coverage on MediWound with a new price target

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target

MediWound Selected For €16.25M Funding From The European Innovation Council Accelerator Program

MediWound Files Amendment To Settlement Agreement With Teva; Under Amendment, Co Will Prepay Teva $4M As Final Payment Due From Company Under Agreement; 50% Of Prepayment In Cash, 50% In Form Of Ordinary Shares Of Co To Be Issued By Co To Teva

Recent Analyst Ratings for
$MDWD

$MDWD
FDA approvals

$MDWD
SEC Filings

$MDWD
Large Ownership Changes

$MDWD
Financials

$MDWD
Leadership Updates

$MDWD
Press Releases

$MDWD
Analyst Ratings

$MDWD
Market Insights